Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis.

Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. This phase I study of Taxotere (RP 56976, NSC 628503; docetaxel, Rhône-Poulenc Rorer, Antony, France) was undertaken to determine the maximum-tolerated dose (MTD), toxic effects, and basic pharmacokinetics of a day-1 and -8 schedule of this novel semisynthetic product related to Taxol (paclitaxel; Bristol-Myers Squibb, Wallingford, CT). http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of clinical oncology : official journal of the American Society of Clinical Oncology Pubmed

Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis.

Tomiak, E; Piccart, M J; Kerger, J; Lips, S; Awada, A; de Valeriola, D; Ravoet, C; Lossignol, D; Sculier, J P; Auzannet, V
Journal of clinical oncology : official journal of the American Society of Clinical Oncology , Volume 12 (7): -1390 – Aug 4, 1994
Download PDF

Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis.


Abstract

This phase I study of Taxotere (RP 56976, NSC 628503; docetaxel, Rhône-Poulenc Rorer, Antony, France) was undertaken to determine the maximum-tolerated dose (MTD), toxic effects, and basic pharmacokinetics of a day-1 and -8 schedule of this novel semisynthetic product related to Taxol (paclitaxel; Bristol-Myers Squibb, Wallingford, CT).

Loading next page...
 
/lp/pubmed/phase-i-study-of-docetaxel-administered-as-a-1-hour-intravenous-Le6o4xTOPY

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
0732-183X
DOI
10.1200/JCO.1994.12.7.1458
pmid
7912725

Abstract

This phase I study of Taxotere (RP 56976, NSC 628503; docetaxel, Rhône-Poulenc Rorer, Antony, France) was undertaken to determine the maximum-tolerated dose (MTD), toxic effects, and basic pharmacokinetics of a day-1 and -8 schedule of this novel semisynthetic product related to Taxol (paclitaxel; Bristol-Myers Squibb, Wallingford, CT).

Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology – Pubmed

Published: Aug 4, 1994

There are no references for this article.